Will Covid 19's ability to mutate affect affect tr
Post# of 72440
(Total Views: 768)
Posted On: 06/14/2020 7:27:53 PM
Will Covid 19's ability to mutate affect affect treatments by therapeutics and vaccines?
IPIX summarizes some of the research on its web page;in the Covid 19 section, the PR and updates section.
https://static1.squarespace.com/static/571535....20.20.pdf
Viruses {and bacteria} have the ability to mutate; that is , they can change their structure in a way to avoid detection from the immune system even when existing antibodies and T cells have previously identified them.
Brilacidin has several characteristics to resist these mutations. The initial research will need to be confirmed by future studies, but current evidence shows Brilacidin has several mechanisms of action:
- it can disrupt the virus's outer coat or capsid
-it can prevent attachment of the spike protein to the cell's receptor protein, the ACE protein
- it can prevent viral replication by inactivating the main protease.
Having multiple mechanisms of action helps neutralize the ability of the virus to escape destruction. It may take millions of viral divisions to produce 1 mutation but to obtain all 3 mutations is millions cubed. Instead of 1,000,000 it would take 1,000,000,000,000,000,000 thus making resistance much less likely.
In addition Brilacidin,s immunomodulating effects may prove helpful in preventing the most common cause of death, pulmonary failure.
Covid 19 patients frequently develop secondary bacterial infections which may be prevented or treated by Brilacidin.
Brilacidin is the only treatment being studied which has all these attributes which is why it is vital it be placed in human studies as soon as possible.
Hopefully the trials are only weeks away since planning has already started.
Good luck,Farrell
IPIX summarizes some of the research on its web page;in the Covid 19 section, the PR and updates section.
https://static1.squarespace.com/static/571535....20.20.pdf
Viruses {and bacteria} have the ability to mutate; that is , they can change their structure in a way to avoid detection from the immune system even when existing antibodies and T cells have previously identified them.
Brilacidin has several characteristics to resist these mutations. The initial research will need to be confirmed by future studies, but current evidence shows Brilacidin has several mechanisms of action:
- it can disrupt the virus's outer coat or capsid
-it can prevent attachment of the spike protein to the cell's receptor protein, the ACE protein
- it can prevent viral replication by inactivating the main protease.
Having multiple mechanisms of action helps neutralize the ability of the virus to escape destruction. It may take millions of viral divisions to produce 1 mutation but to obtain all 3 mutations is millions cubed. Instead of 1,000,000 it would take 1,000,000,000,000,000,000 thus making resistance much less likely.
In addition Brilacidin,s immunomodulating effects may prove helpful in preventing the most common cause of death, pulmonary failure.
Covid 19 patients frequently develop secondary bacterial infections which may be prevented or treated by Brilacidin.
Brilacidin is the only treatment being studied which has all these attributes which is why it is vital it be placed in human studies as soon as possible.
Hopefully the trials are only weeks away since planning has already started.
Good luck,Farrell
(8)
(1)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼